Home/Royalty Pharma/George Lloyd

GL

George Lloyd

Chief Investment Officer

Therapeutic Areas

Oncology Immunology Neurology Respiratory Rare Diseases Infectious Disease

Royalty Pharma Pipeline

Drug	Indication	Phase
Humira	Autoimmune disorders	Commercial
Imbruvica	Blood cancers	Commercial
Spinraza	Spinal muscular atrophy	Commercial
Cabometyx	Renal cell carcinoma	Commercial
Trelegy	COPD/Asthma	Commercial
Trodelvy	Breast cancer	Commercial
Evrysdi	Spinal muscular atrophy	Commercial
Orladeyo	Hereditary angioedema	Commercial

Leadership Team at Royalty Pharma

Pablo Legorreta

Founder and Chief Executive Officer

Chief Financial Officer

James F. Martin

General Counsel and Chief Compliance Officer

Christopher Hite

Chief Business Officer

Head of Research

View full Royalty Pharma profile